Comparison of analyses by clinical criteria in published case reports and by laboratory identification of drug-dependent, platelet-reactive antibodies of 351 drugs that were suspected of causing thrombocytopenia
| Drugs evaluated by laboratory testing . | Clinical criteria . | ||
|---|---|---|---|
| Drugs evaluated by case reports (n = 253) . | Not reported (n = 98) . | ||
| + . | − . | ||
| + (n = 67) | 24 | 22 | 21 |
| − (n = 135) | 19 | 39 | 77 |
| Not tested (n = 149) | 44 | 105 | 0 |
| Total (N = 351) | 87 | 166 | 98 |
| Drugs evaluated by laboratory testing . | Clinical criteria . | ||
|---|---|---|---|
| Drugs evaluated by case reports (n = 253) . | Not reported (n = 98) . | ||
| + . | − . | ||
| + (n = 67) | 24 | 22 | 21 |
| − (n = 135) | 19 | 39 | 77 |
| Not tested (n = 149) | 44 | 105 | 0 |
| Total (N = 351) | 87 | 166 | 98 |
The 351 drugs evaluated by both case reports and laboratory testing are represented by the sum of all rows and columns. The 24 drugs that had evidence for a causal association with thrombocytopenia by both case reports and detection of drug-dependent antibodies are represented in the top left cell. In addition to these 24 drugs, 106 drugs (22 + 21 in the first row and 19 + 44 in the first column) had evidence for a causal association with thrombocytopenia by either published case reports or detection of drug-dependent, platelet-reactive antibodies. Therefore, 130 drugs (24 + 106) had evidence for causal association by either cause reports, detection of drug-dependent antibodies, or both.
+ indicates evidence for a causal association with thrombocytopenia by clinical evidence and/or by detection of drug-dependent antibodies; and −, drugs described in case reports that did not provide evidence for a causal association with thrombocytopenia or that were submitted for laboratory testing for drug-dependent antibodies but for which no such antibodies were identified.